Showing results (551-560 of 3,353) with videos related to

Sort By:
Pageof 336
The Lancet. Oncology|November 19, 2013
Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation studyAnas Younes, Joseph M Connors, Steven I Park, et al.
The Lancet. Oncology|December 17, 2013
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trialCharles Butts, Mark A Socinski, Paul L Mitchell, et al.
The Lancet. Oncology|September 5, 2014
Statins and breast cancer prognosis: evidence and opportunitiesThomas P Ahern, Timothy L Lash, Per Damkier, et al.
The Lancet. Oncology|December 27, 2013
Single versus multiple fractions of repeat radiation for painful bone metastases: a randomised, controlled, non-inferiority trialEdward Chow, Yvette M van der Linden, Daniel Roos, et al.
The Lancet. Oncology|December 17, 2013
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trialHugo E R Ford, Andrea Marshall, John A Bridgewater, et al.
The Lancet. Oncology|December 17, 2013
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trialSusan O'Brien, Richard R Furman, Steven E Coutre, et al.
The Lancet. Oncology|January 21, 2015
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 studyCharles J Ryan, Matthew R Smith, Karim Fizazi, et al.
The Lancet. Oncology|March 8, 2016
Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trialTakuma Higurashi, Kunihiro Hosono, Hirokazu Takahashi, et al.
The Lancet. Oncology|November 25, 2015
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trialFrancesca Gay, Stefania Oliva, Maria Teresa Petrucci, et al.
The Lancet. Oncology|November 25, 2015
Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trialJavier Cortés, Véronique Dieras, Jungsil Ro, et al.
Pageof 336